Table 4.
Sensitivity analyses
| Study endpoints | N | No. of events/Total No. of women |
HR* (95% CI) | P† | |
|---|---|---|---|---|---|
| No RT | RT | ||||
| Excluding NSABP B-14, B-20, and TAILORx (radiotherapy not randomized) | |||||
| RFI | 616 | 43/312 | 17/304 | 2.70 (1.36 to 5.36) | .005 |
| Locoregional RFI | 603 | 37/306 | 10/297 | 4.11 (1.78 to 9.47) | .001 |
| Distant RFI | 570 | 6/275 | 7/295 | 0.95 (0.26 to 3.48) | .94 |
| Excluding TAILORx only | |||||
| RFI | 969 | 44/312 | 54/657 | 2.66 (1.36 to 5.23) | .005 |
| Locoregional RFI | 935 | 37/305 | 27/630 | 3.97 (1.72 to 9.10) | .001 |
| Distant RFI | 906 | 6/275 | 28/631 | 0.99 (0.27 to 3.64) | .98 |
| Including ages 40 to 75 years and older | |||||
| RFI | 2080 | 54/524 | 76/1556 | 2.01 (1.18 to 3.45) | .01 |
| Locoregional RFI | 1994 | 35/501 | 23/1493 | 3.81 (1.88 to 7.72) | <.001 |
| Distant RFI | 1974 | 10/472 | 41/1502 | 0.65 (0.26 to 1.60) | .40 |
| 5-year study duration | |||||
| RFI | 1778 | 22/373 | 37/1405 | 2.55 (1.06 to 6.18) | .04 |
| Locoregional RFI | 1742 | 19/367 | 19/1375 | 3.69 (1.36 to 10.03) | .01 |
| Distant RFI | 1710 | ||||
| 9-year study duration | |||||
| RFI | 1778 | 22/373 | 37/1405 | 2.64 (1.35 to 5.15) | .005 |
| Locoregional RFI | 1742 | 41/367 | 55/1375 | 4.25 (1.58 to 9.81) | .001 |
| Distant RFI | 1710 | 6/335 | 28/1375 | 0.90 (0.25 to 3.19) | .87 |
*
Cox models adjusted for patient age, tumor grade (low, moderate, high, or unknown), ER/PR status (ER+ and PR+ or other), HER2 (negative or unknown), type of initial hormonal treatment (tamoxifen, aromatase inhibitors or other), tumor size, study type, and Oncotype DX recurrence score. RFI = recurrence-free interval; CI = confidence interval; HR = hazard ratio; NSABP = National Surgical Adjuvant Breast and Bowel Project; TAILORx = Trial Assigning IndividuaLized Options for Treatment (Rx).
†
Two-sided P values are based on Student t test.